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Introduction
NK cells play a critical role during the early stages of human 
CMV (HCMV) infection, and the presence of HCMV alters the 
NK compartment (1, 2). The alterations include expansion of 
NKG2C+ cells, changes in expression of signaling molecules lead-
ing to enhanced antibody-dependent cell-mediated cytotoxicity 
(ADCC), and epigenetic changes that regulate cytokine produc-
tion (reviewed in refs. 3, 4). HCMV has several known strategies 
to evade the NK response, such as disrupting the expression of 
ligands for the activating receptor NKG2D by UL16, enhancing 
HLA-E expression via a UL40-derived peptide to inhibit NK cells 
via NKG2A, and expression of the MHCI mimic UL18 (5). NK cells 
are inhibited by UL18 through engagement of the inhibitory recep-
tor leukocyte immunoglobulin-like receptor subfamily B member 
1 (LILRB1) (6, 7). UL18 shares about 25% sequence similarity with 
classical MHCI molecules (8), binds cellular peptides efficiently 
within its binding groove, and associates with β2m. The bulk of the 
molecule is shielded from the adaptive immune system by exten-
sive glycosylation that is noticeably absent from the contact region 
with LILRB1 (8, 9). UL18 binds to the 2 membrane-distal immuno-
globulin domains of LILRB1 (6, 10) in a manner that parallels the 
interaction of LILRB1 with MHCI (11). However, the interface with 
UL18 is substantially larger compared with MHCI, with enhanced 
complementarity, explaining the higher affinity of LILRB1 to UL18 
compared with MHCI (11).
Several observations suggest that the interaction of LILRB1 
with UL18 is important in the immune response to HCMV. In 
transplant patients, higher expression of LILRB1 occurs on 
lymphocytes prior to the onset of viremia (12, 13). LILRB1  is 
expressed  on  NK  cells  that  have  expanded  in response to 
acute HCMV infection (14). In addition, mutations in the α1 
and α3 domains of UL18 among HCMV strains impacts interac-
tion with LILRB1 (15). A recent study indicates that variation in 
UL18 sequence does impact LILRB1+ NK cell control of HCMV 
replication in vitro (16).
LILRB1 exhibits considerable diversity in the population, and 
polymorphisms in the LILRB1 gene have been associated with 
susceptibility to rheumatoid arthritis (17) and weakly associated 
with HCMV disease in a subset of patients with HIV (18). How-
ever, to our knowledge, no studies to date have examined how 
LILRB1 polymorphisms influence the interaction of LILRB1 with 
UL18. LILRB1 is expressed by a variety of immune cells includ-
ing monocytes, DCs, B cells, subsets of effector and memory T 
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the SNPs rs1004443- G, rs3760860- A, and rs3760861- A. Given 
the ability of UL18 to inhibit NK cell responses and the apparent 
importance of NK cells in controlling HCMV replication, we inves-
tigated LILRB1 polymorphisms in transplant patients to test the 
hypothesis that individuals with greater LILRB1 expression on NK 
cells would exhibit poorer control of HCMV replication. In con-
cells, and 20%–70% of NK cells (6, 19, 20). We previously defined 
several haplotypes of the LILRB1 gene and their relationship 
to LILRB1 expression on NK cells in healthy individuals (7, 17, 
21). More specifically, individuals with the SNPs rs1004443-A, 
rs3760860-G, and rs3760861-G have higher levels of LILRB1 
transcript and surface expression on NK cells (7) than those with 
Figure 1. LILRB1 genotype and control of HCMV replication in transplant patients. (A) Schematic illustrating the positions of 5 SNPs analyzed in trans-
plant patients. (B) Disease-free survival rates for HCMV disease of 67 D+/R– Canadian transplant patients genotyped for the indicated SNPs. The P values 
indicated in each graph in Figure 1 were determined by log-rank (Mantel-Cox) test. (C) Incidence of HCMV DNAemia for rs10423364 (n = 762) and rs1061680 
(n = 748) of all the SOT patients from the STCS. (D) Incidence of posttransplant HCMV DNAemia of D+/R– or R+ STCS kidney transplant patients for the 
indicated SNPs (n = 479). (E) Kaplan-Meier curves of HCMV DNAemia disease–free status according to alleles of rs10423364 and rs1061680 in 31 Canadian 
kidney transplant patients.
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rs1061680 but not for rs10423364. The SNP rs10423364 is almost 
in perfect linkage disequilibrium (LD) with SNP rs10416697 
(r2 ~0.96) in the distal promoter and in perfect LD with the proxi-
mal promoter SNP rs1004443 (r2 = 1).
In univariate analysis, there was no association between 
LILRB1 SNPs and virus replication within the entire STCS popula-
tion (Figure 1C). However, when the analyses were restricted to 
kidney transplant recipients (Supplemental Figure 3), we detected 
a significant association with rs10423364 (log-rank test, P = 0.02) 
and a trend for rs1061680 (P = 0.25) with HCMV infection. These 
associations were even more significant when analyses were fur-
ther restricted to HCMV-positive patients (P = 0.005 and P = 0.06, 
respectively; Figure 1D). We found a trend toward higher viremia 
only in the kidney transplant patients in the Canadian cohort. There 
were just 31 patients in total, so significance is unclear (Figure 1E and 
Supplemental Figure 2). There was no association with HCMV dis-
ease (Supplemental Figure 3) in the whole population or within a sub-
set of kidney recipients only. The rates of disease were much lower in 
the STCS cohort, presumably due to the highly selected D+/R– set of 
the Canadian samples. In order to determine whether the association 
with HCMV disease was independent from other covariates, we ana-
lyzed the role of rs1061680 and rs10423364 in multivariate models. 
We first included SNP rs10423364 in the model, since we observed 
that it had the strongest association with HCMV disease (Supplemen-
tal Table 3). The association was still significant in the multivariate 
model (HR = 1.69; 95% CI, 1.13–2.54; P = 0.01) after adjustment for 
donor and recipient age and sex, use of corticosteroid, cyclosporine 
and tacrolimus regimen, rejection episodes, use of antiviral prophy-
laxis, and HCMV serostatus. We included both SNPs in the multivari-
ate stepwise model, but only rs10423364 remained independently 
associated with HCMV. No significant association was observed with 
killer cell immunoglobulin-like receptor (KIR) haplotypes that were 
further entered in the model, perhaps due to the smaller sample size 
or due to association of the KIR locus, which is also encoded within 
the leukocyte receptor complex located on chromosome 19. There 
was no significant association with HCMV when using rs1061680 
instead of rs10423364, either with or without adjustment for KIR 
variables (HR = 1.46; 95% CI 0.92–2.32; P = 0.1). Altogether, these 
data reveal a possible role for a genetic variation in LILRB1 in the con-
trol of HCMV replication in STCS cohort kidney transplant patients. 
The stronger association with rs10423364 than with rs1061680 in the 
larger cohort may be due to the most important SNP(s) being located 
in the interval between these 2 SNPs. The interval between rs1004443 
and rs1061680 contains several SNPs, including 2 additional 
nonsynonymous changes in the first immunoglobulin domain. The 
2 SNPs located in the gene regulatory region are in perfect LD (r2 
= 1) and share the same LD value with rs1061680 (r2 = 0.76) (Table 
1). Among the other 3 known nonsynonymous SNPs in the binding 
domain (D1D2) coding region of LILRB1, rs1061679 (L/P) is also in 
strong LD with the 3 SNPs that we found were associated with HCMV 
infection (r2 = 0.92), but rs12460501 (A/T) and rs1061681 (S/I) are not 
(Table 1). Based on previous studies of LILRB1 polymorphisms by our 
laboratory and others (7, 17) and data drawn from the 1000 Genomes 
Project (24), there is 1 major haplotype and several minor LILRB1 
haplotypes that combine the 4 nonsynonymous SNPs located in the 
D1D2 coding region, as shown in Figure 2. According to the published 
3D structures, none of the residues affected by the polymorphisms 
trast to our expectations, the results revealed that the emergence 
of alleles conferring lower frequency of LILRB1+ NK cells may be 
an adaptation to limit the expression of receptor variants that are 
more susceptible to manipulation by UL18. In spite of the adapta-
tion, individuals with lower frequency of LILRB1+ NK cells remain 
disadvantaged in controlling HCMV under immunosuppression.
Results
LILRB1 polymorphisms and HCMV viremia in transplant patients. 
To test whether LILRB1 genotype influences HCMV susceptibil-
ity, we analyzed LILRB1 genotypes in a small group of Canadian 
transplant patients (22). The number of samples available for this 
retrospective analysis was only 67, but all patients enrolled in the 
study were HCMV seronegative prior to receiving an organ from 
an HCMV-positive donor and therefore predisposed to high rates 
of primary HCMV disease (Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI96174DS1). All patients received antiviral prophylaxis for 3–6 
months to prevent HCMV primary infection and were followed 
for 1 year after transplantation for incidence of HCMV asymp-
tomatic infection (50%) and disease (25%). We analyzed 5 SNPs 
spread throughout the LILRB1 gene that encompass the known 
regulatory regions, a nonsynonymous change in binding domain, 
and the cytoplasmic region of the protein (Figure 1A). We used 
rs10416697 (–14895 from the translational start in the distal pro-
moter region) and rs1004443 (–1026), which form extended hap-
lotypes in the regulatory domains (Supplemental Figure 1A). The 
third SNP (rs2781771) is at –225 relative to the start codon and 
the minor allele is quite rare. The fourth SNP (rs1061680) causes 
a nonsynonymous substitution in the second immunoglobulin 
domain of the receptor previously examined in the context of HIV 
and HCMV (18). The final and most 3′ SNP tested is at position 
+5724 relative to the translational start (rs16985478), with a sec-
ond nonsynonymous change in the cytoplasmic tail that encodes 
a potential ubiquitination site (7). Given the limited sample size, 
only trends could be ascertained. Counter to our prediction that 
patients with more LILRB1+ NK cells would have a higher inci-
dence of HCMV disease, we found that homozygous carriers of 
the minor allele at rs10416697 were more prone to presenting with 
HCMV disease (50% in C/C vs. 23% in T/C+T/T; Fisher’s exact 
test, P = 0.166; log-rank test, P = 0.0873) (Figure 1B and Supple-
mental Figure 2). Results for rs1004443 are identical to rs10416697 
(data not shown) and there is a slightly more pronounced trend for 
rs1061680. There was no substantial difference in the incidence of 
HCMV disease in patients with different genotypes for rs2781771 
or rs16985478 (Figure 1B).
We next examined a larger cohort to validate the putative 
association of LILRB1 SNP rs1061680 and HCMV asymptomatic 
infection and/or disease using patients from the Swiss Transplant 
Cohort Study (STCS) (23). Genotype data for both rs1061680 and 
its potential surrogate upstream SNP rs10423364 (r2 ~0.8) were 
available for 1,018 STCS solid organ transplant (SOT) recipients 
of European descent, of which 76% had donor and/or recipient 
HCMV-positive serostatus (Supplemental Table 2). Of the 776 
seropositive patients, 651 had received kidneys, and of those kid-
ney recipients, 74% had donor and/or recipient HCMV-positive 
serostatus. An additional 100 patients had genotype data for 
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lead to major changes in the con-
formation of the receptor. We con-
firmed the function of the receptors 
in YTS cells using 221 cells express-
ing HLA-G and the antibody W6/32 
to block the recognition of HLA-G 
and prevent the inhibition of YTS 
cells (Supplemental Figure 5). Lysis 
of 221 cells by YTS-LAIS and YTS-
PTTI was similarly and reproduc-
ibly reduced compared with paren-
tal YTS cells (Figure 3D, top panel), 
but the difference did not reach a 
measurable level of significance in 
aggregated data (Figure 3D, bottom panel). The lower lysis of the 
MHCI-deficient target is likely due to the expression of LILRB1 
tempering the signaling in YTS cells in a cell-intrinsic manner. 
The lysis of 221 cells bearing HLA-Cw15 or UL18 was lower for 
YTS-PTTI (Figure 3C) compared with YTS-LAIS (Figure 3D), sug-
gesting a better interaction by PTTI. There was no significant dif-
ference between the 2 LILRB1 variants with the more potent ligand 
HLA-G (Figure 3D, lower panel). Treatment with HPF1 antibody 
to block LILRB1 function increases the lysis of Cw15, UL18, and 
HLA-G target cells to the same level as YTS cells, demonstrating 
that receptor interaction with the ligand is indeed inhibiting the 
YTS cells (Figure 3E).
LILRB1 binding with HLA-I molecules and viral UL18. To probe 
the relationship of polymorphisms with the binding properties of 
the variants, we generated Fc-tagged versions of the D1 and D2 
domains of the 2 LILRB1 variants. The 2 variants bind equally well 
to the antibody HPF1 as previously reported (17). The LAIS vari-
ant migrated slightly faster than the PTTI variant by SDS-PAGE 
analysis (Figure 4). We compared binding of the Fc fusion protein 
to 221 cells expressing MHCI ligands over a range of concentra-
tions at 4°C as detected by flow cytometry. The raw binding data 
are illustrated in Supplemental Figure 6. The signal was higher 
at all concentrations for the PTTI-Fc variant compared with the 
LAIS-Fc variant with HLA-Cw15 and HLA-B58 (Figure 4C). 
Consistent with the functional assays (Figure 3), binding of the 
2 variants to cells expressing HLA-G was similar. The binding 
was not saturated, which precludes formal comparison of half-
maximal binding concentrations. The binding specificity was 
demonstrated by blocking with the antibody W6/32 (Figure 4D). 
We next compared the binding of the LILRB1 variants to 221 
cells expressing UL18. We observed lower binding of LAIS-Fc 
compared with PTTI-Fc (Figure 4E), although the difference in 
binding to UL18 was less pronounced than with HLA-Cw15 and 
HLA-B58. We performed a reciprocal binding assay using puri-
fied UL18 Fc fusion protein and HA-tagged full-length LILRB1-
PTTI and -LAIS expressed on RBL cells normalized to the recep-
tor levels using α-HA and HPF1, respectively (Figure 4F). Again, 
make direct contact with UL18 or HLA-A2, although they do all 
align on the same face of the receptor. The residues proline/leucine 
and threonine/alanine corresponding to rs1061679 and rs12460501, 
respectively, are located near the interface, whereas residues 
threonine/isoleucine and isoleucine/serine corresponding to 
rs1061680 and rs1061681, respectively, are localized quite far away 
(Supplemental Figure 4A). Furthermore, the leucine to proline 
change can have substantial impact on protein structure and confor-
mational dynamics because proline introduces rigidity into the back-
bone and leucine is a larger hydrophobic residue.
LILRB1 variants differ for functional inhibition of NK cells. To 
test potential functional differences between the LILRB1 vari-
ants, we established an in vitro system with conventional 721.221 
tumor targets expressing surface UL18. The 721.221 cell line was 
transduced with retroviral vector encoding UL18 with HA tag at 
the N-terminus and yellow fluorescent protein (YFP) at the C- 
terminus. UL18 expression levels are shown as measured with 
anti-HA and the intrinsic YFP expression relative to the parental 
cell line (Figure 3A).
To directly compare the function of the 2 LILRB1 variants 
that differ at all 4 polymorphic positions in D1D2, we expressed 
the 2 variants denoted as LAIS and PTTI in LILRB1-negative NK 
cells. We transduced YTS cells with HA-tagged LAIS-LILRB1 and 
HA-tagged PTTI-LILRB1, and selected subclones with similar sur-
face expression levels of LILRB1 by flow cytometry using histone 
PARylation factor 1 (HPF1) and α-HA (Figure 3B). The similar ratio 
of HA to HPF1 suggests that the 4 amino acid differences do not 
Table 1. LD acquired from the 1000 Genomes Project phase 1 on European populations
LD(r2) rs10416697 rs10423364 rs1004443 rs1061679 rs12460501 rs1061680 rs1061681
rs10416697 – 0.98 0.98 0.91 0.22 0.76 0.50
rs10423364 – 1.00 0.92 0.22 0.76 0.50
rs1004443 – 0.92 0.22 0.76 0.50
rs1061679 – 0.24 0.68 0.53
rs12460501 – 0.29 0.28
rs1061680 – 0.65
rs1061681 –
Bold indicates SNPs analyzed in transplant patients.
Figure 2. Natural protein variants deduced from the 1000 Genomes 
Project for the first 2 Ig domains of LILRB1. The location of the 4 non-
synonymous SNPs and corresponding amino acids are indicated with the 
haplotype proportions shown on the right. Bold indicates the LILRB1 vari-
ants tested in the functional assay.
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variants on SDS-PAGE (Figure 4A), and a finding that the addi-
tional carbohydrate was important for binding would explain the 
discrepancy with the previous report due to their production of the 
receptors in E. coli.
Residue T119 is required for glycosylation of N117, and it differ-
entially influences ligand binding. To test whether glycosylation of 
PTTI was responsible for the difference in migration, we treated 
the purified Fc fusion proteins with N-glycosidase. Treatment with 
N-glycosidase under denaturing conditions resulted in the 2 LILRB1 
variants running at a similar size (Figure 5B). To investigate whether 
the N-linked glycosylation plays a role in LILRB1-PTTI binding, 
LILRB1-PTTI bound better to UL18-Fc than LILRB1-LAIS most 
clearly at the highest concentration tested (900 nM), although the 
assay was limited by the amount of UL18-Fc available (Figure 4G).
The results of the binding assays are consistent with the differ-
ences observed in the functional assays, although it is unclear why 
differences in binding with MHCI were not observed by Kuroki et 
al. (17). Residue N117 is predicted to be glycosylated in LILRB1-
PTTI but not LILRB1-LAIS due to the presence of a threonine resi-
due at position 119 (ref. 17 and Figure 5A). An additional N-linked 
carbohydrate in PTTI at residue 117 would also explain the differ-
ence in migration that we observed between the LAIS and PTTI 
Figure 3. Functional activity of LILRB1-PTTI and -LAIS variants. (A) Expression of HA–UL18-YFP on 
transduced 721.221 cells (left). MFIs are corrected for background staining in each case. (B) Surface 
expression of LILRB1 on YTS cells and LILRB1-transduced YTS cells detected with α-HA or α-LILRB1 
(HPF1). (C) Surface expression of MHCI on transduced 721.221 cells detected with W6/32. (D) Specific 
lysis of 721.221 cells; 721.221 cells presenting HLA-Cw15, HLA-G, and UL18 by YTS; and YTS cells 
expressing LILRB1. Upper panel: representative result from 6 independent assays with 3 E/T ratios. 
Lower panel: aggregated result of 6 experiments at an E/T of 10:1; error bars indicate SD. *P < 0.05 
determined by paired samples t test. (E) Lysis was determined in the presence of 10 μg/ml α-LILRB1 
(HPF1) or isotype control IgG1κ at an E/T of 10:1. Results are aggregated from 3 independent tests. 
Error bars indicate SD. *P < 0.05 as determined by paired samples t test.
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we mutated the asparagine residue at position 117 to glutamine 
(N117Q). The N117Q–PTTI-Fc receptor comigrated with LAIS-Fc, 
and the N117Q mutation in LAIS-Fc did not alter its mobility in a 
gel (Figure 5C). The N117Q mutation in the 2 mutants also did not 
change the reactivity with HPF1 as detected by ELISA (Figure 5D). 
As predicted, the binding of N117Q-PTTI to HLA-Cw15 was dimin-
ished to a level similar to LAIS (Figure 5E). N117Q–LAIS-Fc binding 
with Cw15 was unchanged compared with LAIS-Fc and was close to 
the limit of detection (Figure 5E). Somewhat unexpectedly, muta-
tion of residue 117 to a glutamine in PTTI and LAIS reduced binding 
to HLA-G; however, the 2 mutants still bound similarly to HLA-G 
(Figure 5E). These observations suggest that in addition to being a 
site for glycosylation in PTTI, residue N117 in LAIS influences the 
interaction with HLA-G without being glycosylated. Surprisingly, 
N117Q substitution enhanced the binding of both LILRB1 variants 
to UL18, with similar binding curves (Figure 5E). These results point 
to the importance of residue 117 and its modification being impor-
tant in the interaction of LILRB1 with various endogenous and viral 
ligands even if there is not an obvious explanation for the enhanced 
binding of the N117Q mutant.
All 4 residues contribute greatly to the interaction between UL18 
and MHCI. To directly test whether residue T119 influences bind-
ing and is involved in the glycosylation of PTTI, we used site- 
directed mutagenesis to generate the variants PTII and LTTI to 
test the role of residue P45 in this interaction. PTII comigrates with 
LAIS, confirming the effect of T119 on migration and glycosylation 
(Figure 6A). PTII does not alter reactivity with HPF1 (Figure 6B). 
Consistent with our prediction that T119 influences the interac-
tion of Cw15 and UL18, binding of PTII-Fc to Cw15 and UL18 was 
reduced compared with PTTI (Figure 6C). Substitution of the 
proline residue at position 45 to leucine also significantly reduced 
the interaction with UL18 and Cw15, almost as much as the T119I 
mutation. These 2 mutations also reduced binding to HLA-G.
To address the role of T90 and I132, we generated the corre-
sponding versions of the D1D2 domains with the combinations 
PATI and PTTS as Fc fusion proteins. As expected, PATI-Fc and 
PTTS-Fc migrated more slowly than LAIS-Fc, similar to PTTI-Fc 
(Figure 6D), and there was no difference in reactivity with HPF1 
(Figure 6E). PATI bound to all ligands with similar efficiency as 
LAIS, with reduced binding to both HLA-Cw15 and UL18 (Figure 
6F). These results suggest that only NK cells with the PTTI vari-
ant would be well inhibited by UL18, and predict that PATI behaves 
similarly to LAIS, although it is associated with polymorphisms in 
the promoter region leading to low frequency of expression on NK 
cells. The presence of a serine at position 132 in the context of a 
receptor with PTT in the first 3 variable positions reduces the bind-
ing with UL18 relative to PTTI and, remarkably, has a dramatic 
enhancing effect on HLA-G binding (Figure 6F).
Predicted structural consequences of LILRB1 polymorphisms. We 
have demonstrated that substitution of each of the 4 residues sig-
nificantly influences binding to both classical MHCI molecules 
and to the CMV-associated MHCI mimic UL18. In order to evalu-
ate the structural consequences of the LILRB1 polymorphism on 
its interactions with each MHC/peptide, we created a 3D model 
for each MHC/peptide in complex with each LILRB1 variant (see 
Methods for details). Superposition of the 3 structurally deter-
mined LILRB1 variants demonstrates angle differences between 
the D1D2 domains, which could have a substantial impact on 
the capacity of each LILRB1 variant to interact with each studied 
MHC/peptide complex (Supplemental Figure 4B). Comparison of 
the 3 complexes (Figure 7, A–C) indicates that although the overall 
interaction is similar, several of the polymorphisms result in the 
large observed differences in affinity.
The main difference between HLA-A2 and HLA-G in their 
respective interaction with LILRB1-PATI is the sequence and 
conformation of a loop localized between the β strands of the 
α3 domain. Indeed, the stretch of HLA-A2 residues (S195-
D196-H197) and the corresponding stretch of residues in HLA-G 
(F195-D196-Y197) are different in conformation and properties 
(Figure 7, D–F). These polymorphisms result in substantial changes 
in the side chains of 2 residues (S195F and H197Y), both in size and 
properties. Furthermore, the conformation of the loop is very dif-
ferent in HLA-G compared with classical HLA molecules, substan-
tially altering the binding interface. These structural comparisons, 
although largely based on molecular modeling, provide a potential 
explanation for the differential binding of LILRB1 to UL18, HLA-
Cw15, and HLA-G.
Consistent with the binding data, the LILRB1 residue P45 
plays an important role in interactions with UL18 (Figure 7D) in 
the model. Although P45 is localized at 4.2 Å from the UL18 resi-
due N199, it affects the conformation of the side chain of N199, 
facilitating the formation of a hydrogen bond between N199 and 
residue T43 in LILRB1. In addition, the small and rigid residue P45 
allows UL18 residues N201 and D202 to come closer to LILRB1 
and form a hydrogen bond with the backbone of L37 in LILRB1 
and a salt bridge between the LILRB1 residue R84 and the UL18 
residue D202 (Figure 7D). Comparison of LILRB1-LAIS (Protein 
Data Bank [PDB] code 1vdg) with any other LILRB1 structure indi-
Figure 4. Binding of soluble LILRB1 variants to HLA-I molecules and HCMV-UL18. (A) Representative analysis of purified LILRB1 D1D2-Fc fusion proteins 
by Coomassie blue staining (left) and α–human IgG Fc Western blot (right). (B) Reactivity with α-LILRB1 (HPF1) was determined by ELISA over the indi-
cated range of concentration of the LILRB1-Fc protein. Results shown are the average of 3 independent tests for the same batch of protein; error bars rep-
resent SD. (C) The top histograms illustrate binding of purified LILRB1-Fc to 221 cells with HLA-B58, HLA-Cw15, and HLA-G by flow cytometry at 50 μg/ml. 
The middle panels show 1 representative titration plotted as the MFI. The bottom series of plots show the normalized binding results aggregated from 3 
independent tests. *P < 0.05 using 1-way ANOVA. (D) Cells expressing HLA-I were incubated with 10 μg/ml α-MHCI (W6/32) or the isotype antibody before 
addition of 50 μg/ml LILRB1 variants or Fc control. The binding was measured by flow cytometry. The plots shown are a representative result of 3 indepen-
dent tests. (E) Binding of LILRB1–D1D2-Fc variants to UL18 expressed on 721.221 cells. The flow histogram on the left shows the binding of UL18 with 100 
μg/ml Fc fusion proteins. The middle plot shows a representative experiment across 4 concentrations. The far-right graph shows the aggregate data for 3 
experiments normalized as described in Methods (*P < 0.05 using 1-way ANOVA). (F) Expression of the LILRB1-PTTI and -LAIS variants on transduced RBL 
cells was measured by α-HA or α-LILRB1 (HPF1) staining (representative of 3 independent tests). (G) UL18-Fc binding to LILRB1 variants expressed on RBL 
cells shown in F with a representative histogram shown on the left at 300 nmol. The binding data are normalized by the MFI for α-HA (middle) or α-LILRB1 
(HPF1) (far right). The results are representative of 3 independent tests.
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structures of the PATI- and LAIS-LILRB1 alleles (Supplemental 
Figure 7B). The PATI- and LAIS-LILRB1 molecules have differ-
ent conformations in several loops within the D2 domain. Resi-
due N146 forms a hydrogen bond with Y177 and S132 in PATI 
and LAIS, respectively, resulting in marked conformational dif-
ferences in the loop. In addition, the I132S substitution creates a 
cavity within the hydrophobic core of the D2 domain that allows 
residues W185 and Y177 to move closer to the C134-C144 disul-
fide bridge in order to fill this cavity in LAIS. This movement pulls 
residue E184 further away from the β2m residue K91, reducing the 
interaction of LAIS-LILRB1 with HLA/UL18.
Discussion
We initially speculated that low LILRB1 expression on NK cells 
would allow for enhanced control of HCMV infection due to 
reduced inhibition by the viral MHCI homolog UL18. In contrast 
to our predictions, we found that polymorphisms that predict lower 
frequency of expression on NK cells are directly associated with 
poor control of HCMV in transplant patients. The association of 
the alleles with lower expression can make sense because we have 
also shown that the LILRB1 protein variant encoded by one of the 
alleles interacts more strongly with UL18. We showed that individ-
ual substitution of each one of the 4 polymorphic amino acids in 
the ligand binding domains significantly alters the physical inter-
action of the LILRB1 receptor with UL18. Surprisingly, the poly-
morphisms also change the binding with classical MHCI proteins. 
The natural LILRB1 variants tested maintain strong interaction 
with HLA-G, whereas individual amino acid modification either 
reduces or enhances interaction with HLA-G. Together, these data 
indicate that LILRB1 interaction with HLA-G is a dominant selec-
cated no significant structural changes in D1 or D2. Substitution of 
P45 to a leucine larger than P45 repels the UL18 residue N199 and 
distorts the interface established between UL18 and the LILRB1-
PATI variant.
The LILRB1 residue A70 is localized in the hinge region that 
connects the 2 immunoglobulin domains D1 and D2 in LILRB1 
(Supplemental Figure 7A). Comparison of the crystal structures 
of the 2 LILRB1 alleles PATI and PTTI (Supplemental Figure 4B) 
reveals clear differences in the angle between D1 and D2. The 
flexibility between D1 and D2 is very important, since it is known 
that LILRB1 changes the interdomain angle by 15° upon complex 
formation (17). In addition, the crystal structures show clear dif-
ferences in the conformation of specific loops within the inter-
domain region, which are part of site 1 in interactions with UL18 
and HLA-A2. The A70T polymorphism could directly impact the 
hinge region, since the hydroxyl group of T70 in PTTI forms a 
hydrogen bond with the carboxyl group of residue E184 in the D2 
domain (Supplemental Figure 7A, left). This interaction not only 
can affect the angle formed between D1 and D2 and/or the flex-
ibility of those domains, but it also alters the conformation of E184 
(Supplemental Figure 7A, right). Residue E184 forms a strong salt 
bridge in the crystal structures of both the LILRB1/HLA-0201 
and LILRB1/UL18 complexes (25, 26). It should also be noted 
that the substitution of E184V is considered to be one of the main 
causes underlying the distinct binding mode between LILRB1 and 
LILRB2 (27). Thus, the substitution of residue A70 to a threonine 
will indirectly alter the interaction between the LILRB1 variant 
PTTI and MHC molecules.
Finally, the functional effect of the isoleucine to serine muta-
tion at position 132 can be explained by comparing the crystal 
Figure 5. Mutation of the putative glycosylation site alters binding. (A) The sequence surrounding the putative N-linked glycosylation site NVT at posi-
tion 117 is shown for both variants. The region boxed in red illustrates the target sequence NVT, present only in the variants with T at position 119. (B) 
LILRB1-PTTI and -LAIS variants treated with N-glycosidase analyzed by SDS-PAGE and Western blot. Lanes 1–2 are KIR3DL1-Fc, 3–4 are LILRB1-PTTI-Fc, 
5–6 are LILRB1-LAIS-Fc, and 7 is the molecular weight marker. (C) Representative SDS-PAGE and Coomassie blue staining of the LILRB1-Fc N117Q-PTTI and 
N117Q-LAIS mutants. Lanes from left to right indicate the protein ladder, LILRB1-PTTI-Fc, N117Q-PTTI-Fc, LILRB1-LAIS-Fc, and N117Q-LAIS-Fc. (D) Reactiv-
ity with α-LILRB1 (HPF1) for the mutated LILRB1 by ELISA. Results shown are the average of 3 independent tests for the same batch of protein; error bars 
represent SD. (E) Fc fusion protein binding to cells expressing the ligands at the top was measured by flow cytometry as before. Significance testing was 
performed between the binding of each artificial mutants and PTTI. *P < 0.05, ns = P ≥ 0.05 using 1-way ANOVA. The plots are the normalized binding 
results aggregated from at least 3 independent tests (4 and 5 independent tests for HLA-G and UL18, respectively).
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cosylation of the UL18 surface outside the area of known LILRB1 
interaction likely precludes additional points for contact. An addi-
tional possibility is that the residues influence the dimerization of 
the receptor in a manner similar to what has been suggested for the 
related KIR inhibitory receptors, where formation of higher-order 
complexes may be involved in signal transduction (28). However, 
it is difficult to imagine how formation of higher-order complexes 
would have similar effects for MHCI and UL18 but not HLA-G.
The similar binding that we observed of HLA-G with natural 
variants compared with the artificial combinations we generated 
suggests that maintaining interaction with HLA-G within a par-
ticular threshold provides selective pressure on diversification of 
LILRB1. HLA-G is best known for its expression in the placenta, 
where it is presumed to modulate the environment to prevent 
immune-mediated fetal rejection (29). Introduction of a serine at 
position 132 into the PTTI variant significantly augmented binding to 
HLA-G, but this combination does not occur at any appreciable 
frequency as a natural variant (24). The LAII haplotype is carried by 
2.7% of the European population; it is a variant likely to have lower 
affinity for HLA-G and that could influence reproduction. Perhaps 
LILRB1 polymorphism is relevant in cancer, as HLA-G expression 
on cancer cells is associated with poor outcomes (30, 31).
The overall effect of LILRB1 genotype on control of HCMV 
is relatively mild. The SNP with the highest significance differs 
between the 2 cohorts, although they both map the same extend-
tive force maintaining LILRB1 haplotypes, whereas alleles with 
higher affinity for UL18 have adapted through selective regulation 
of LILRB1 expression on NK cells in order to limit evasion of NK 
responses by HCMV. The structural analysis provides a possible 
explanation for how residues that are outside the binding interface 
influence the interaction between LILRB1 and UL18. It remains to 
be determined which polymorphism can best predict outcomes 
with HCMV and whether differences in interaction with classical 
MHCI influence the function of LILRB1 in other cell types and with 
other pathogens.
The rather dramatic effect caused by introducing an isoleucine 
at position 119 to generate PTII suggests that glycosylation influ-
ences binding, and likely explains why an earlier study did not 
detect any differences in affinity using proteins generated in bacte-
ria (17). The glycan could interact directly with UL18, but it is more 
likely to contribute by stabilizing a particular conformation that 
favors binding, perhaps influencing the angle of the hinge. What 
remains difficult to explain is why introduction of glutamine into 
position 117 disrupted binding to Cw15 and HLA-G, while simulta-
neously enhancing binding to UL18 for both variants. It is possible 
that there is a steric hindrance with UL18 due to its glycosylation, 
which is not found on MHCI. Another possibility, although not 
mutually exclusive, is that the residues are part of a second func-
tional interface of the receptor because all of the polymorphic resi-
dues are located on the same face. The near-total coverage by gly-
Figure 6. Contributions of each residue to binding. (A and D) Migration of LILRB1–D1D2-Fc fusion protein mutants as detected by Coomassie blue stain-
ing. (B and E) Reactivity of the LILRB1–D1D2-Fc fusion proteins with α-LILRB1 (HPF1) measured by ELISA. Results shown are the average of 3 independent 
tests for the same batch of protein; error bars represent SD. (C and F) Normalized binding aggregated from 3 independent tests. Significance testing was 
performed between the binding of each artificial mutant and PTTI. *P < 0.05 using 1-way ANOVA.
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It is not entirely clear why the correlation between LILRB1 
genotype and susceptibility to HCMV infection is pronounced in 
STCS kidney transplant patients or why a similar skewing for vire-
mia was observed in the D+/R– group from Canada. The results 
of this study need to be viewed with the standard qualification for 
analysis of subgroups as well as the reduction of the sample size, 
but the results are also strengthened by the similarity of the out-
comes between the 2 cohorts in terms of the extended haplotype 
that associates with more HCMV (disease or viremia). In both 
cohorts, the kidney is the predominant organ type, with the liver 
being the second most frequent organ type. The organ distribu-
tion has obvious implications, since liver recipients are typically 
ed haplotype that correlates with less frequent LILRB1 expres-
sion on NK cells. Further dissecting which SNPs control expres-
sion in NK cells and which influence binding should refine any 
further examinations of the genetic association with CMV repli-
cation. Our results are in agreement with higher rates of HCMV 
disease in a subgroup of HIV+ patients with a threonine at posi-
tion 119 (18). Future studies that assess SNPs within the interval 
between rs1004443 and rs1061680 may locate the most predic-
tive SNPs. For example, a stronger association may be revealed 
with removal of the variants encoding alanine at rs124060501, 
as this subset has weak binding to UL18 and the frequency of 
PATI haplotypes is 12%.
Figure 7. P45L has larger effects on the 
UL18/LILRB1 interaction compared with 
MHCI/LILRB1. Comparison of the 3D 
structures of 3 complexes, including the 
crystal structure of UL18/LILRB1 (A) and 
the molecular models of HLA-Cw15/LILRB1 
(B) and HLA-G/LILRB1, (C) illustrates the 
similarity of their binding modes as well 
as important differences in the details of 
these interactions. Proteins are displayed 
as cartoons with heavy chains of UL18 and 
HLA molecules in different pink colors, the 
β2m subunit in green, and LILRB1 in light 
cyan. The 4 residues that differ between the 
LILRB1 alleles are shown as yellow spheres. 
(D) Conformation of P45L in LILRB1 inter-
acting with UL18 compared with the com-
plexes formed with HLA-Cw15 (E) or HLA-G 
(F). LILRB1 is in light cyan, and the chains of 
UL18 or HLA are pink. Residues important 
for the interactions are displayed as sticks.
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repertoire in humans (reviewed in ref. 62). Our results demonstrate 
that a small change in affinity between LILRB1 and UL18 can greatly 
influence control of HCMV after transplantation. Our findings have 
opened many new questions about the potential effect of LILRB1 
variation in other HCMV-mediated pathologies, and they emphasize 
the importance of maintaining an appropriate level of LILRB1 inter-
action with HLA-G. The apparent imprint of UL18 on the evolution 
of LILRB1 underscores the influence of highly adapted pathogens 
on the human genome and implies similar relationships with other 
pathogens that could shape the NK cell receptor repertoire.
Methods
Genotyping of transplant patients
The Canadian cohort SNP study consisted of a post hoc analysis of 
all the local patients included in a multicenter cohort study, and no 
Canadian patients were excluded from the post hoc analysis. Access 
to patient specimens from the remaining sites was considered to be 
impractical and was not pursued. All relevant information regard-
ing sample size calculation, recruitment, enrollment, and inclusion/ 
exclusion criteria, as well as a flowchart summarizing the recruitment 
process for the entirety of the multicenter cohort study, is available in 
the original article (22). Briefly, patients were enrolled at the time of 
transplantation and received HCMV antiviral prophylaxis. Viremia 
was measured, as HCMV DNAemia and HCMV disease (63) were 
tracked for the first year after transplantation. Samples were genotyped 
using Taqman, and the associations were determined in isolation or in 
combination (i.e., heterozygous individuals with homozygous carriers 
of either the major or minor alleles). Associations between SNP geno-
types and outcomes were investigated for the entire cohort and also 
separately for each participating center.
The association of LILRB1 SNP rs1061680 and its surrogate SNP 
rs10423364 (r2 ~0.8) with HCMV infection or disease was determined 
in patients from the STCS (23). The STCS is a prospective, national 
cohort of SOT recipients involving 6 hospital centers in Switzerland 
(Lausanne, Geneva, Zurich, St. Gallen, Bern, Lugano, and Basel). 
Each SOT recipient within Switzerland who had signed, informed 
consent was recruited to the cohort. Each patient’s clinical data were 
collected at baseline, 6 months after transplantation, and continue to 
be collected every 12 months after transplantation on standardized 
data forms by local physicians and data managers. Samples for genetic 
study (either whole blood or PBMCs) were collected from each patient 
at enrollment. CMV was monitored either in plasma or whole blood by 
using PCR arrays.
This study included all STCS SOT recipients recruited between 
May 2008 and November 2013, for whom all clinical data were avail-
able. In order to maintain consistency regarding allele frequencies, the 
analyses were limited to patients of European descent. Furthermore, 
patients who had incomplete or no genetic data and those whose 
DNA samples did not pass a quality check were excluded. Finally, we 
restricted our study to high-risk patients with a positive donor and/
or recipient CMV serostatus. Genotype data for both rs1061680 and 
rs10423364 were available for 1,018 STCS SOT recipients of European 
descent (776 with donor and/or recipient HCMV-positive serostatus; 
Table 1). Kidney recipients accounted for 651 of the study subjects (479 
with donor and/or recipient HCMV-positive serostatus). An additional 
100 patients had genotype data for rs1061680 but not for rs10423364.
at a lower risk for HCMV infection and disease, likely decreasing 
the strength of the association between HCMV replication and the 
genotypes when the overall cohorts (i.e., all organ types) are taken 
into consideration. In the Swiss cohort data set genotyped for 
rs10423364, the rate of HCMV infection in kidney recipients was 
33.79% vs. 28.32% in recipients of other organ types. The Canadian 
patients were all HCMV D+/R–, with a much higher incidence 
of HCMV disease than what is seen in the Swiss cohort (25% vs. 
<6%), in which approximately 76% of the recipients were HCMV 
seropositive. The difference may explain why in the latter group 
we see a genotype effect only for viremia. In a previous study using 
patients from the STCS, the association with the KIR genotype 
was seen predominantly in patients receiving the highest level of 
immune suppression—specifically, heart and lung recipients as 
well as kidney recipients given antithymocyte globulin (ATG) (32). 
However, we found KIR and LILRB1 to be independent variables 
in STCS samples despite their close proximity to one another with-
in the leukocyte receptor complex.
Two previous studies might provide an alternative explana-
tion for our results, as they suggest a potential protective influ-
ence of LAIS and the related variants. A very recent study showed 
that certain UL18 variants that differ from AD169 not only fail to 
inhibit NK cells but in fact stimulate LILRB1+ NK cells (16). The 
study did not take into account the LILRB1 variants, but it did 
show that the stimulation required LILRB1. Another, earlier study 
demonstrated that LILRB1+ T cells are stimulated through UL18 
even though LILRB1 inhibits T cells in other situations, suggest-
ing the signal transmitted by LILRB1 may be context dependent 
(33–38). Since many HCMV-specific effector/memory T cells are 
LILRB1+, the role of LILRB1 variation in T cell responses should be 
considered as well. The contribution of LILRB1 interaction with 
MHCI may also be a factor. In our earlier study, we found that few 
if any LILRB1+ NK cells respond to classical MHCI; however, it is 
unlikely a PTTI homozygous donor was tested (39).
The significance of the association of LILRB1 SNPs with HCMV 
disease is that it may be useful as part of a collection of biomark-
ers used to determine the relative risk for patients after receiving 
a transplant and to guide prophylactic use of antivirals in these 
patients. Many studies have investigated genetic influences on the 
immune response to HCMV; the genes implicated in modulating 
the control of HCMV after transplantation include IL-28B, CCL8, 
several microRNA, CLTA4, TLR9, DC-SIGN, and, most relevant 
to NK cells, NKG2C and KIRs (40–56). Further studies with addi-
tional cohorts could be useful to pinpoint the SNPs with the best 
correlation and to explore the relationship to the sequence of UL18 
within each patient. Another interesting implication of the present 
work relates to prenatal and perinatal infection with HCMV. HCMV 
is the leading cause of birth defects resulting from infection, and 
estimates of permanent damage are as high as 0.1% of births. Deaf-
ness is the most frequent problem, and it is more prevalent in a pri-
mary infection (57). LILRB1 is expressed by myeloid cells within the 
decidua as well as NK cells (58), and LILRB1 variation might be a 
factor in controlling transmission of the virus to the fetus or infant.
Studies of mouse CMV (MCMV) contributed much to the under-
standing of adaptive NK cell responses and evolution of NK cell 
receptor systems in response to the virus (59–61). A substantial body 
of work has established the effect of HCMV infection on the NK cell 
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For the 221 cells with stable expression of HA–UL18-YFP, HCMV 
strain AD169-derived UL18 was provided by Lewis Lanier. The cod-
ing sequence was amplified with primers that replaced the stop codon 
with an in-frame sequence that allowed fusion to YFP using BamH1 
and the pEYFP-N1 plasmid (Clontech) with linker sequence RDP-
PVAT. UL18-YFP was amplified by PCR with appropriate restric-
tion sites and subcloned into pDisplay in frame with the N-terminal 
HA-tag generating a linker of GAQPARSPGIRGCRSS. The resulting 
construct was sequenced, and an apparent PCR error was corrected by 
site-directed mutagenesis. The construct was subcloned into pMXs-
puro (pMXs-HA–UL18-YFP). Phoenix cells (2.5 × 106) were plated in 
a 60-mm dish for 16 hours and transfected with 8–15 μg pMXs-HA–
UL18-YFP plasmid using calcium phosphate precipitation. After the 
incubation for 8 hours at 37°C/5% CO2, the medium was replaced with 
3 ml 721.221 medium and cells were further incubated for 48 hours at 
32°C/5% CO2. The supernatant was added to 5 × 105 721.221 cells with 
8 μg/ml Polybrene (Sigma-Aldrich), plated in 1 ml in a 24-well plate, 
spun at room temperature for 90 minutes at 365 RCF, and incubated 
for 3 hours at 37°C/5% CO2. The cells were pelleted again and cultured 
in fresh medium in a T25 flask for 48 hours and then selected with 1 
μg/ml puromycin (Bioshop Canada Inc.) replacing with fresh medium 
every 3–4 days. When cultures returned to confluence, UL18 surface 
expression was assessed by flow cytometry. Single-cell clones were 
obtained by the limiting dilution and surface expression detected with 
α-HA antibody by flow cytometry.
LILRB1-Fc fusions and variants. The LAIS-LILRB1–D1D2-Fc has been 
previously described (65). For more efficient protein production we gen-
erated a new plasmid by moving the CD5 leader sequence and Fc region 
from CD5neg1 (gift from Eric Long) to the pEGFP (Clontech) backbone 
and removing the EGFP cassette (Fc-simple). The PTTI-LILRB1–D1D2 
domains were moved into the Fc-simple plasmid using PCR to generate 
an in-frame fragment with EcoR1 sites. The plasmids encoding the other 
LILRB1 mutants including PTII, LTTI, PATI, and PTTS were generated 
based on Fc-simple PTTI by site-directed mutagenesis.
Cytotoxicity assay
Effector cells were counted by TC20 Automated Cell Counter (Bio-
Rad Laboratories) and diluted to 106 cells/ml with RPMI 1640 medium 
supplemented with 10% FBS. Calcein-AM (Life Technologies) was dis-
solved in anhydrous DMSO (Life Technologies) at 100 μM and stored 
for up to 1 week. Target cells were adjusted to 5 × 106 cells/ml and 
labeled in the medium with 3.5 μM calcein for 30 minutes at 37°C/5% 
CO2. Calcein-labeled cells were washed twice with 10 ml RPMI medium 
and counted and diluted to 5 × 104 cells/ml. For 10:1 of the E/T ratio 
reaction in each well of a 96-well plate, 50 μl 106 cells/ml effector cells 
and 100 μL 5 × 104 cells/ml target cells were added in triplicate.
Where required, 50 μl of 10 μg/ml HPF1 or MOPC-21 or medium 
were prealiquoted into a V-bottom 96-well plate (Corning). RPMI 
media (100 μl) and/or RPMI containing 2% Triton X-100 were 
added to target cells for the spontaneous and maximum release, 
respectively. The plate was incubated at 37°C/5% CO2 for 4 hours 
and spun at 6 RCF for 2 minutes. Supernatant (100 μl) was trans-
ferred to the black flat-bottom 96-well plate (Corning), and calcein 
release was measured in the EnSpire 2300 Multilabel Reader (Perki-
nElmer). Specific lysis was calculated based on the formula for each 
well: 100 × (release read – spontaneous release) / (maximum release – 
spontaneous release).
Cell lines and antibodies
YTS cells were obtained from Eric Long (NIH, Bethesda, Maryland, 
USA) as a gift and cultured with Iscove’s modified Dulbecco’s medium 
(IMDM) with 15% characterized FBS (ThermoFisher Scientific), 50 
μM β-mercaptoethanol, and 1 mM l-glutamine. The human B lym-
phoma cell line 721.221 and 721.221 cells transfected with HLA-B58, 
HLA-Cw15, and HLA-G originally obtained through Eric Long were 
maintained in IMDM (Gibco, ThermoFisher Scientific) with 10% FBS 
(Gibco, ThermoFisher Scientific) and supplemented with 0.5 mg/ml 
G418 sulfate (Life Technologies). Phoenix and Cos-7 cells were pur-
chased from ATCC and cultured in DMEM (Gibco, ThermoFisher 
Scientific) with 10% FBS. RBL cells were obtained from James Staf-
ford (University of Alberta, Edmonton, Alberta, Canada) and main-
tained in MEM (ThermoFisher Scientific) containing 10% FBS. Puri-
fied unconjugated mouse α–human CD85j (clone: HPF1, IgG1κ) (20) 
was provided by Miguel López-Botet (Pompeu Fabra University, Bar-
celona, Spain). Alexa Fluor 647–conjugated α-HA (clone: 16B12) and 
IgG1κ isotype (clone: MOPC-21) were purchased from BioLegend. 
Unconjugated and APC-conjugated mouse α–human CD85j (clone: 
HPF1, IgG1κ) and mouse IgG1κ isotype control APC-conjugated 
antibodies were purchased from eBioscience. Mouse IgG1κ isotype 
control (clone: MOPC-21) was purchased from Sigma-Aldrich. α–
Human HLA-I (clone: W6/32) and α–human CD8 (clone: 51.1) were 
purified from hybridoma supernatants (ATCC). Goat α–human IgG Fc 
(catalog: 109-005-098) was from Jackson ImmunoResearch. Phyco-
erythrin (PE)–conjugated mouse α–human IgG Fc (catalog: 9042-09) 
was from SouthernBiotech.
Receptor constructs and transfections
Full-length LILRB1 was amplified from the cDNA of a donor with 
known LAIS homozygous genotype. The coding sequence of the 
LILRB1 was amplified without the signal peptide using primers with 
restriction site additions (XmaI at the 5′ end and SalI at the 3′ end). 
The amplified genes were cloned into the TOPO pCRII vector using a 
TOPO-TA cloning kit (ThermoFisher Scientific). The LILRB1 gene was 
digested out of the pCR-II vector and cloned into the pDisplay expres-
sion vector (ThermoFisher Scientific), in frame with the HA tag. The 
PTTI variant of LILRB1 was produced using sequential site-directed 
mutagenesis of the LAIS variant in pCRII. Site-directed mutagenesis 
was done following the manufacturer’s instructions for the QuikChange 
Lightning Mutagenesis kit (Agilent Technologies). Each mutation was 
confirmed by sequencing of the insert. The PTTI variant was digested 
out of the pCRII vector and cloned into the pDisplay vector.
RBL transfection. RBL cells (1.5 × 105) were plated in a 6-well plate 
in 1 ml of medium overnight. The medium was replaced with 250 μl 
Opti-MEM (ThermoFisher Scientific) prior to addition of 1 μg plasmid 
(HA-PTTI-LILRB1 or HA-LAIS-LILRB1 in pDisplay) and transfected 
using Xfect Transfection Reagent (Clontech) essentially according to 
the manufacturer’s instructions. The cells were incubated for 4 hours 
at 37°C/5% CO2, and then 750 μl RBL media was added and the cells 
were cultured for another 48 hours. The medium was replaced with RBL 
medium containing 800 μg/ml G418. G418-resistant cells were sorted 
by flow cytometry for matching levels of receptor using α-HA antibody 
and continuously cultured in 800 μg/ml G418. HA-tagged LILRB1-
PTTI and -LAIS were subcloned into pMXs-puro vector (gift from Lewis 
Lanier, UCSF, San Francisco, California, USA) using ClaI and NotI 
restriction sites. YTS cells were transduced as previously described (64).
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All modeling was performed manually in Coot (67). The 3D model 
of LILRB1/HLA-Cw15 was created using LILRB1/HLA-A2 as a tem-
plate. The 3-domain of HLA-Cw15 differs from HLA-A2 in only 4 res-
idues, and none of these polymorphisms are present in the HLA/LIL-
RB1 contact area. Thus, we hypothesized that the HLA-Cw15 binding 
mode should be similar to that of HLA-A2. We created the model 
of the HLA-G/LILRB1 complex based on the crystal structure of 
LILRB1/HLA-A2, replacing HLA-A2 with HLA-G (27).
In order to evaluate the structural consequences of the LILRB1 
polymorphism, we created several 3D models. Crystal structures are 
available for 2 other allelic variants of LILRB1: LAIS (PDB code 1vdg) 
and PTTI (PDB code 1ugn) (17). Substitution of the PATI variant in the 
crystal structures of LILRB1/UL18 and LILRB1/HLA-A2 with LAIS or 
PTTI allowed us to evaluate the impact of these polymorphic residues on 
the structure of the complexes. Following replacement of the subunits 
in the models, energy minimization was performed using the sphere- 
regularization option in Coot. The model geometry as well as the con-
formation of the main chain (Ramachandran plot) were validated for 
all models in Coot. PyMol was used for preparation of all structural fig-
ures (PyMol Molecular Graphics System, version 1.5.0.4, Schrödinger).
Statistics
Two-tailed Pearson χ2 or Fisher’s exact test was utilized to test for asso-
ciations between categorical variables. Log-rank test was utilized to 
compare the Kaplan-Meier curves showing disease-free survival rates 
for HCMV DNAemia or disease. The associations of LILRB1 polymor-
phism and HCMV infection or disease were assessed by using univari-
ate log-rank test and Cox regression models with censoring at 12 months 
after transplantation or until the date when the patient was lost to fol-
low-up or died. In the multivariate Cox regression model, genetic asso-
ciations were adjusted for relevant covariates as identified in a previous 
genetic association study of HCMV infection in the same cohort (40). 
Those variables included donor/recipient age, sex, and any appropriate 
covariates associated with the endpoint. Genetic associations were 
assessed using the recessive mode of inheritance (patients carrying 2 
copies of the minor alleles are compared with the others). KIR genotypes 
were also used as covariates in a subset of 590 SOT recipients (including 
263 kidney recipients) who had available genotypes. The LD, Hardy- 
Weinberg equilibrium (HWE) test, and minor allele frequency (MAF) 
were assessed by using the pwld and hwe software implemented in 
Stata 14 (StataCorp). The cutoff of r2 > 0.8 was used to denote strong LD 
between studied polymorphisms. All SNPs passed the HWE test. For 
YTS killing assay, the means of the calculated specific lysis rates were 
compared by 2-tailed paired samples t test with significance of P < 0.05. 
For the flow cytometry–based binding assay, each mean fluorescence 
intensity (MFI) value was corrected by subtraction of the Fc control MFI 
and then divided by the arithmetic average of the entire sample MFI in 1 
independent test. The results of the binding assay were aggregated from 
at least 3 independent tests, and 1-way ANOVA was used to compare the 
binding of different purified proteins with a specific ligand. P values less 
than 0.05 were considered significant. Statistical analysis was performed 
with SPSS Statistics 20 (IBM) and Prism v5.0 (GraphPad). Except as oth-
erwise indicated, the experimental data are presented as mean ± SD.
Study approval
Initial IRB approval for the Canadian cohort was obtained on 
January 30, 2009, under study ID Pro00002140. Additional IRB 
Purification of LILRB1–D1D2-Fc fusion protein
Plasmids containing the variants and artificial mutants of LILRB1 
D1D2 domains were amplified in E. coli and extracted by GenElute 
HP Plasmid Midiprep Kit (Sigma-Aldrich). Cos-7 cells seeded in 
T150 flasks were transfected with 20 μg DNA per flask. Cells were 
washed with DMEM 3 times at 12 hours after transfection and then 
maintained in serum-free DMEM with 1% NEAA (ThermoFisher 
Scientific). Medium was collected and changed every 3 days (3 times) 
and filtered for affinity purification. The medium was loaded to a 
column filled with Protein A/G beads (Millipore) at 4°C, and the col-
umn was washed with PBS and then eluted by 0.05 M glycine. Eluted 
protein was neutralized by 1 M Tris buffer and dialyzed into PBS with 
Amicon centrifugal filters (Millipore). A protease inhibitor cocktail 
(Roche) was subsequently added to the purified protein. Concentra-
tion was determined using a Micro BCA kit (ThermoFisher Scien-
tific). Purity and specificity were verified by Coomassie blue staining 
and Western blotting, respectively, using α–human IgG Fc. Capture-
based ELISA was used to check the conformation consistency of the 
purified LILRB1 variants and artificial mutants using HPF1, which 
targets the D1 and D2 domains of LILRB1 (64). Purified human IgG 
Fc fragment control has been previously described (64).
LILRB1 binding assay
The 221 cells were counted and their concentration adjusted to 2 × 
107/ml with FACs buffer (2% FBS and 1 mM EDTA in PBS). Fc fusion 
protein (10 μl) was added to 10 μl cells in a 1.5-ml Microfuge (Thermo-
Fisher Scientific) tube and incubated for 1 hour at 4°C with rotation, 
washed with 4 ml FACs buffer, and then incubated with 100 μl 5 μg/ml 
PE mouse α–human IgG Fc for 30 minutes at 4°C. Cells were washed 
again, fixed with 4% formaldehyde, and analyzed on an LSRFortessa 
analyzer (Becton Dickinson). Compensation was required for the YFP 
spill into the PE channel for binding to UL18-expressing cells. Where 
indicated, 100 μl 10 μg/ml W6/32 or isotype control was preincubated 
with the cells at 4°C for 10 minutes, and the cells were washed with 
FACs buffer prior to adding the Fc fusion protein.
The UL18-Fc fusion was generated as previously described (66). 
To account for the difference in the expression of LILRB1-PTTI and 
-LAIS variants on RBL cells, the binding was normalized by staining 
LILRB1 with α-HA or HPF1.
Deglycosylation
Potential N-linked glycosylation sites were predicted with GlycoEP 
(IMTECH, http://www.imtech.res.in/raghava/glycoep/index.html). 
For enzymatic deglycosylation, 2 μg purified proteins was adjusted to 
43 μl with 250 mM NaHPO4 buffer (pH 7.5) and then mixed with 2.5 
μl denaturing buffer containing 2% SDS and 1 M β-mercaptoethanol, 
and incubated at 100°C for 5 minutes. The mixture was cooled to room 
temperature, and 2.5 μl 10% Triton X-100 detergent was added with 
2 μl N-glycosidase F from Elizabethkingia meningosepticum (Millipore) 
and incubated for 3 hours at 37°C. Samples were separated by 10% 
SDS-PAGE and stained by Coomassie blue.
Three-dimensional modeling
The crystal structures of the LILRB1/HLA-A2 and LILRB1/UL18 
complexes have been previously determined using the PATI-LILRB1 
variant (25, 26). We created 3D models of LILRB1/HLA-Cw15 and 
LILRB1/HLA-G based on the crystal structures mentioned above. 
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